Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38677 | 0.86 | MAOB (0.39) | — | |
| SCHEMBL11656752 | 0.84 | MAOB (0.38) | — | |
| SCHEMBL27554229 | 0.82 | DAPK1 (0.32) | — | |
| SCHEMBL38468 | 0.82 | PLAU (0.33) | PLAUPLAT | |
| Tetrazole SCHEMBL11228500 | 0.79 | CA2 (0.30) | — | |
| SCHEMBL27418632 | 0.75 | CYP19A1 (0.39) | PLAUPLAT | |
| SCHEMBL7516288 | 0.75 | CYP19A1 (0.39) | — | |
| SCHEMBL27815218 | 0.75 | DHFR (0.35) | PLAU | |
| SCHEMBL10636487 | 0.74 | MAOB (0.31) | — | |
| SCHEMBL28977388 | 0.74 | CYP19A1 (0.38) | PLAUPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571973-B1 | OPTICAL BRIGHTENERS AND COMPOSITIONS COMPRISING THE SAME | MILLIKEN & CO (US) | 2020-04-01 | — | — | EP | disclosed |
| US-8740997-B2 | Optical brighteners and compositions comprising the same | MILLIKEN & COMPANY (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130281347-A1 | OPTICAL BRIGHTENERS AND COMPOSITIONS COMPRISING THE SAME | MILLIKEN & COMPANY | 2013-10-24 | — | — | US | disclosed |
| US-8454711-B2 | Optical brighteners and compositions comprising the same | MILLIKEN & COMPANY (US) | 2013-06-04 | — | — | US | disclosed |
| EP-2571973-A2 | OPTICAL BRIGHTENERS AND COMPOSITIONS COMPRISING THE SAME | Milliken & Company (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20120329699-A1 | OPTICAL BRIGHTENERS AND COMPOSITIONS COMPRISING THE SAME | MILLIKEN & COMPANY (US) | 2012-12-27 | — | — | US | disclosed |
| US-8262744-B2 | Optical brighteners and compositions comprising the same | MILLIKEN & COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| WO-2011146604-A2 | OPTICAL BRIGHTENERS AND COMPOSITIONS COMPRISING THE SAME | MILLIKEN & COMPANY (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110287999-A1 | OPTICAL BRIGHTENERS AND COMPOSITIONS COMPRISING THE SAME | MILLIKEN & COMPANY | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110287999-A1 | OPTICAL BRIGHTENERS AND COMPOSITIONS COMPRISING THE SAME | DBN1, AOC1, RARB | PLAU 1622/4885PLAT 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.